HC Wainwright Reiterates Buy Rating for Agenus (NASDAQ:AGEN)

Agenus (NASDAQ:AGEN – Get Rating)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a report issued on Tuesday, MarketBeat reports. They presently have a $8.00 price target on the biotechnology company’s stock. HC Wainwright’s target price would indicate a potential upside of 312.37% from the stock’s previous close. HC Wainwright also issued estimates for Agenus’ Q4 2023 earnings at ($0.20) EPS and FY2027 earnings at ($0.34) EPS.

AGEN has been the subject of a number of other reports. StockNews.com downgraded shares of Agenus from a “hold” rating to a “sell” rating in a report on Monday, November 14th. EF Hutton Acquisition Co. I initiated coverage on shares of Agenus in a report on Thursday, December 22nd. They set a “buy” rating and a $8.30 price objective for the company. One analyst has rated the stock with a sell rating and three have assigned a buy rating to the company. According to data from MarketBeat, Agenus has a consensus rating of “Moderate Buy” and an average target price of $7.33.

Agenus Price Performance

Shares of Agenus stock opened at $1.94 on Tuesday. Agenus has a fifty-two week low of $1.25 and a fifty-two week high of $3.37. The firm has a fifty day moving average price of $2.42 and a two-hundred day moving average price of $2.53. The company has a market cap of $591.34 million, a PE ratio of -2.40 and a beta of 1.32.

Hedge Funds Weigh In On Agenus

Hedge funds and other institutional investors have recently made changes to their positions in the business. U.S. Capital Wealth Advisors LLC bought a new position in shares of Agenus during the 1st quarter worth about $25,000. Calamos Advisors LLC acquired a new stake in shares of Agenus during the 4th quarter worth about $27,000. Commonwealth Equity Services LLC acquired a new stake in shares of Agenus during the 3rd quarter worth about $26,000. Leisure Capital Management acquired a new stake in shares of Agenus during the 3rd quarter worth about $26,000. Finally, Nisa Investment Advisors LLC increased its position in shares of Agenus by 441.4% during the 2nd quarter. Nisa Investment Advisors LLC now owns 13,860 shares of the biotechnology company’s stock worth $27,000 after purchasing an additional 11,300 shares in the last quarter. 53.81% of the stock is owned by institutional investors.

About Agenus

(Get Rating)

Agenus, Inc is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H.